Tectonic Therapeutic Announces Start of First Clinical Program for GPCR-Targeted Biologic
“The start of our first-in-human study is a critical and exciting milestone.
- “The start of our first-in-human study is a critical and exciting milestone.
- We look forward to seeing the potential of relaxin biology realized in patients,” said Alise Reicin, MD, President and Chief Executive Officer, Tectonic Therapeutic.
- Because of these features, it offers a similarly broad range of potential therapeutic applications with significant benefits expected in cardio-pulmonary diseases.
- We look forward to future clinical programs emerging from Tectonic’s platform.”